Download presentation
Presentation is loading. Please wait.
Published byAlexander Tucker Modified over 9 years ago
1
www.escardio.org/guidelines European Heart Journal 2010 European Heart Rhythm Association (EHRA); Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) ESC Guidelines 2010 on the management of Atrial Fibrillation European Heart Journal (2010) 31, 2369-2429
2
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429
3
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Classes of recommendations
4
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Levels of evidence
5
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Clinical Events (outcomes) affected by AF
6
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Conditions predisposing to, or encouraging progression of AF
7
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Types of Atrial Fibrillation
8
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Clinical evaluation
9
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Structural abnormalities associated with AF
10
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 EHRA score of AF- related symptoms AF = atrial fibrillation; EHRA = European Heart Rhythm Association
11
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Natural time course of AF AF = atrial fibrillation
12
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Diagnosis and initial management of AF a Class of recommendation. b Level of evidence. AF = atrial fibrillation; ECG = electrocardiogram; EHRA = European Heart Rhythm Association.
13
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Diagnosis and initial management of AF a Class of recommendation. b Level of evidence. AF = atrial fibrillation; ECG = electrocardiogram.
14
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Diagnosis and initial management of AF a Class of recommendation. b Level of evidence. AF = atrial fibrillation; ECG = electrocardiogram.
15
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 The management cascade for patients with AF ACEI = angiotensin-converting enzyme inhibitor; AF = atrial fibrillation; ARB = angiotensin receptor blocker; PUFA = polyunsaturated fatty acid; TE = thrombo-embolism.
16
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 CHADS 2 score and stroke rate *The adjusted stroke rate was derived from the multivariable analysis assuming no aspirin usage; these stroke rates are based on data from a cohort of hospitalised AF patients, published in 2001, with low numbers in those with a CHADS 2 score of 5 and 6 to allow an accurate judgement of the risk in these patients. Given that stroke rates are declining overall, actual stroke rates in contemporary non-hospitalised cohorts may also vary from these estimates. Adapted from Gage BF et al. AF = atrial fibrillation; CHADS 2 = cardiac failure, hypertension, age, diabetes, stroke (doubled).
17
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Risk factors for stroke and thrombo-embolism in non-valvular AF AF= atrial fibrillation; EF = ejection fraction (as documented by echocardiography, radionuclide ventriculography, cardiac catheterization, cardiac magnetic resonance imaging, etc.); LV = left ventricular; TIA = transient ischaemic attack.
18
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Risk factor-based point-based scoring system - CHA 2 DS 2 -VASc *Prior myocardial infarction, peripheral artery disease, aortic plaque. Actual rates of stroke in contemporary cohorts may vary from these estimates.
19
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Adjusted stroke rate according to CHA 2 DS 2 -VASc score
20
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Use of oral anticoagulation for stroke prevention in AF AF = atrial fibrillation; OAC = oral anticoagulant; TIA = transient ischaemic attack.
21
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Approach to thromboprophylaxis in AF AF = atrial fibrillation; CHA 2 DS 2 -VASc = cardiac failure, hypertension, age ≥ 75 (doubled), diabetes, stroke (doubled)- vascular disease, age 65–74 and sex category (female); INR = international normalized ratio; OAC = oral anticoagulation, such as a vitamin K antagonist (VKA) adjusted to an intensity range of INR 2.0–3.0 (target 2.5).
22
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 The HAS-BLED bleeding risk score *Hypertension is defined as systolic blood pressure > 160 mmHg. INR = international normalized ratio.
23
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Cardioversion, TOE and anticoagulation AF = atrial fibrillation; DCC = direct current cardioversion; LA = left atrium; LAA = left atrial appendage; OAC = oral anticoagulant; SR= sinus rhythm; TOE= transoesophageal echocardiography.
24
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Prevention of thromboembolism in AF
25
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Prevention of thromboembolism in AF
26
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 a Class of recommendation. b Level of evidence. AF = atrial fibrillation; CHADS2 = cardiac failure, hypertension, age, diabetes, stroke (doubled); INR = international normalized ratio; LMWH = low molecular weight heparin; OAC = oral anticoagulant; TIA = transient ischaemic attack; VKA = vitamin K antagonist. Prevention of thromboembolism in AF
27
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Drugs and doses for pharmacological conversion of (recent-onset) AF ACS = acute coronary syndrome; AF = atrial fibrillation; DCC = direct current cardioversion; i.v. = intravenous; N/A = not applicable; NYHA, New York Heart Association; p.o. = per os; QRS = QRS duration; QT = QT interval; T-U = abnormal repolarization (T-U) waves.
28
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 DCC and pharmacological conversion recent-onset AF AF = atrial fibrillation; i.v. = intravenous.
29
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Pharmacological cardioversion of AF a Class of recommendation. b Level of evidence. AF = atrial fibrillation; LoE = level of evidence; i.v. = intravenous.
30
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 DC cardioversion for AF a Class of recommendation. b Level of evidence. AF = atrial fibrillation; DCC = direct current cardioversion.
31
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 General Management of the AF Patient
32
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Choice of rate and rhythm control strategies
33
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Rate and rhythm control of AF a Class of recommendation. b Level of evidence. AF = atrial fibrillation; EHRA = European Heart Rhythm Association.
34
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Optimal level of heart rate control
35
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Rate control of atrial fibrillation The choice of drugs depends on life style and underlying disease
36
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Drugs for rate control ER = extended release formulations; N/A = not applicable. ‡ Only in patients with non-permanent atrial fibrillation.
37
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Acute rate control in AF a Class of recommendation. b Level of evidence. AF = atrial fibrillation; i.v. = intravenous.
38
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Long-term rate control in AF a Class of recommendation. b Level of evidence. AF = atrial fibrillation; bmp = beats per minute; LV = left ventricular; NYHA = New York Heart Association.
39
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Long-term rate control in AF a Class of recommendation. b Level of evidence. AF = atrial fibrillation; bmp = beats per minute; LV = left ventricular; NYHA = New York Heart Association.
40
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 AV node ablation in AF patients a Class of recommendation. b Level of evidence. AF = atrial fibrillation; AV = atrioventricular; CRT = cardiac resynchronization therapy; LV = left ventricular; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association.
41
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 AV node ablation in AF patients a Class of recommendation. b Level of evidence. AF = atrial fibrillation; AV = atrioventricular; CRT = cardiac resynchronization therapy; LV = left ventricular; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association.
42
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Choice of pacemakers after AV node ablation a Class of recommendation. b Level of evidence. AF = atrial fibrillation; AV = atrioventricular; CRT = cardiac resynchronization therapy; LV = left ventricular; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association.
43
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Principles of antiarrhythmic drug therapy to maintain sinus rhythm 1.Treatment is motivated by attempts to reduce AF-related symptoms. 2.Efficacy of antiarrhythmic drugs to maintain sinus rhythm is modest. 3.Clinically successful antiarrhythmic drug therapy may reduce rather than eliminate recurrence of AF. 4.If one antiarrhythmic drug ‘fails’ a clinically acceptable response may be achieved with another agent. 5.Drug-induced proarrhythmia or extra-cardiac side-effects are frequent. 6.Safety rather than efficacy considerations should primarily guide the choice of antiarrhythmic agent.
44
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Suggested doses and main caveats for commonly used antiarrhythmic drugs AF = atrial fibrillation; AV = atrioventricular; bpm = beats per minute; CYP = cytochrome P; ECG = electrocardiogram; LV = left ventricular; NYHA = New York Heart Association.
45
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Suggested doses and main caveats for commonly used antiarrhythmic drugs (Contd) AF = atrial fibrillation; AV = atrioventricular; bpm = beats per minute; CYP = cytochrome P; ECG = electrocardiogram; LV = left ventricular; NYHA = New York Heart Association.
46
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Suggested doses and main caveats for commonly used antiarrhythmic drugs (Contd) AF = atrial fibrillation; AV = atrioventricular; bpm = beats per minute; CYP = cytochrome P; ECG = electrocardiogram; LV = left ventricular; NYHA = New York Heart Association.
47
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Choice of antiarrhythmic for the patient with no or minimal structural heart disease
48
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Choice of antiarrhythmic drug according to underlying pathology ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; CAD = coronary artery disease; CHF = congestive heart failure; HT = hypertension; LVH = left ventricular hypertrophy; NYHA = New York Heart Association; unstable = cardiac decompensation within the prior 4 weeks. Antiarrhythmic agents are listed in alphabetical order within each treatment box. ? = evidence for ‘upstream’ therapy for prevention of atrial remodelling still remains controversial.
49
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Choice of an antiarrhythmic drug for AF control a Class of recommendation. b Level of evidence. AF = atrial fibrillation; AV = atrioventricular; LoE = level of evidence; NYHA = New York Heart Association.
50
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Choice of an antiarrhythmic drug for AF control a Class of recommendation. b Level of evidence. AF = atrial fibrillation; AV = atrioventricular; LoE = level of evidence; NYHA = New York Heart Association.
51
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Choice of an antiarrhythmic drug for AF control a Class of recommendation. b Level of evidence. AF = atrial fibrillation; AV = atrioventricular; LoE = level of evidence; NYHA = New York Heart Association.
52
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Choice between ablation and antiarrhythmic drug therapy for patients with and without structural heart disease † More extensive LA ablation may be needed; *usually PVI is appropriate. AF = atrial fibrillation; CAD = coronary artery disease; CHF = congestive heart failure; HT = hypertension; LVH = left ventricular hypertrophy; NYHA = New York Heart Association; PVI = pulmonary vein isolation. Antiarrhythmic agents are listed in alphabetical order within each treatment box.
53
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Left atrial catheter ablation a Class of recommendation. b Level of evidence. AF = atrial fibrillation; i.v. = intravenous; LMWH = low molecular weight heparin; OAC = oral anticoagulant; UFH = unfractionated heparin.
54
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Left atrial catheter ablation a Class of recommendation. b Level of evidence. AF = atrial fibrillation; i.v. = intravenous; LMWH = low molecular weight heparin; OAC = oral anticoagulant; UFH = unfractionated heparin.
55
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Surgical ablation of AF a Class of recommendation. b Level of evidence. AF = atrial fibrillation.
56
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Primary prevention of AF with “upstream” therapy a Class of recommendation. b Level of evidence. ACEI = angiotensin-converting enzyme inhibitor; AF = atrial fibrillation; ARB = angiotensin receptor blocker.
57
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Secondary prevention of AF with “upstream” therapy a Class of recommendation. b Level of evidence. ACEI = angiotensin-converting enzyme inhibitor; AF = atrial fibrillation; ARB = angiotensin receptor blocker.
58
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Rate control during AF with heart failure a Class of recommendation. b Level of evidence. AF = atrial fibrillation; AP = accessory pathway; LVEF = left ventricular ejection fraction.
59
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Rate control during AF with heart failure a Class of recommendation. b Level of evidence. AF = atrial fibrillation; AV = atrioventricular; CRT = cardiac resynchronization therapy; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association.
60
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Rhythm control of AF in heart failure a Class of recommendation. b Level of evidence. AF = atrial fibrillation; DCC = direct current cardioversion; NYHA = New York Heart Association.
61
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Atrial Fibrillation in athletes a Class of recommendation. b Level of evidence. AF = atrial fibrillation.
62
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Atrial Fibrillation in valvular heart disease a Class of recommendation. b Level of evidence. AF = atrial fibrillation; INR = international normalized ratio; LA = left atrial; LV = left ventricular.
63
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Atrial Fibrillation in acute coronary syndromes a Class of recommendation. b Level of evidence. AF = atrial fibrillation, ACS = acute coronary syndrome; DCC = direct current cardioversion.
64
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Atrial Fibrillation in : a Class of recommendation. b Level of evidence. AF = atrial fibrillation, ECG = electrocardiogram.
65
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Atrial Fibrillation in pregnancy a Class of recommendation. b Level of evidence. AF = atrial fibrillation; DCC = direct current cardioversion; LMWH = low molecular weight heparin; UFH = unfractionated heparin; VKA = vitamin K antagonist.
66
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Atrial Fibrillation in pregnancy a Class of recommendation. b Level of evidence. AF = atrial fibrillation; DCC = direct current cardioversion.
67
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Post-operative Atrial Fibrillation a Class of recommendation. b Level of evidence. AF = atrial fibrillation; DCC = direct current cardioversion.
68
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Post-operative Atrial Fibrillation a Class of recommendation. b Level of evidence. AF = atrial fibrillation; DCC = direct current cardioversion.
69
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Atrial Fibrillation in hyperthyroidism a Class of recommendation. b Level of evidence. AF = atrial fibrillation.
70
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 AF in Wolff-Parkinson-White syndrome a Class of recommendation. b Level of evidence. AF = atrial fibrillation; AP = accessory pathway; ECG = electrocardiogram; SCD = sudden cardiac death..
71
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 AF in hypertrophic cardiomyopathy a Class of recommendation. b Level of evidence. AF = atrial fibrillation; DCC = direct current cardioversion; HCM = hypertrophic cardiomyopathy; INR = international normalized ratio.
72
www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Atrial Fribillation in pulmonary disease a Class of recommendation. b Level of evidence. AF = atrial fibrillation; DCC = direct current cardioversion.
73
www.escardio.org/guidelines European Heart Rhythm Association (EHRA); Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) European Heart Journal (2010) 31, 2369-2429
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.